ArticleFrontiers in oncology2026
A rare case of primary bladder malignant melanoma: a case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary melanoma of the bladder is an extremely rare malignant tumor. In recent years, only a few sporadic cases have been reported. We report a 59-year-old male patient who presented with gross hematuria and had bladder irritation symptoms such as frequent urination, urgency, and pain. CT imaging showed multiple exophytic small nodules on both sides of the bladder; under cystoscopy, multiple coral-like neoplasms were visible on both sides of the bladder, with no obvious bleeding on the surface, and the largest one was approximately 1.5 cm × 1.2 cm. No evidence of primary melanoma in other parts was found during the comprehensive examination. After the patient underwent transurethral resection of bladder tumor, he received regular intravesical instillation of epirubicin hydrochloride treatment. No recurrence was observed during the 5-month follow-up period. There were no more than 50 cases of primary bladder melanoma reported globally. Further immunohistochemistry should be performed as far as we know, this case is the first report of primary bladder malignant melanoma in Bijie City, Guizhou Province. The prognosis of this disease is generally poor, and its clinical diagnosis is relatively difficult. Immunohistochemistry plays a crucial role in its diagnosis. Due to insufficient understanding of it, there is currently no unified treatment standard.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.